Drugs Containing Excipient (Inactive Ingredient) CYSTEINE HYDROCHLORIDE

« Back to Dashboard

Branded drugs containing CYSTEINE HYDROCHLORIDE excipient, and estimated key patent expiration / generic entry dates

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Eli Lilly and Company	TAUVID	flortaucipir f-18	0002-1220	CYSTEINE HYDROCHLORIDE	2032-05-26
Novartis Pharmaceuticals Corporation	VANRAFIA	atrasentan	0078-1420	CYSTEINE HYDROCHLORIDE	2034-07-07
Hikma Pharmaceuticals USA Inc	COMBOGESIC IV	acetaminophen and ibuprofen injection	0143-9150	CYSTEINE HYDROCHLORIDE	2036-01-14
GlaxoSmithKline LLC	WELLBUTRIN	bupropion hydrochloride	0173-0947	CYSTEINE HYDROCHLORIDE

Generic drugs containing CYSTEINE HYDROCHLORIDE excipient

Company	Ingredient	NDC	Excipient
Eli Lilly and Company	flortaucipir f-18	0002-1220	CYSTEINE HYDROCHLORIDE
Novartis Pharmaceuticals Corporation	atrasentan	0078-1420	CYSTEINE HYDROCHLORIDE
Hikma Pharmaceuticals USA Inc	acetaminophen and ibuprofen injection	0143-9150	CYSTEINE HYDROCHLORIDE
GlaxoSmithKline LLC	bupropion hydrochloride	0173-0947	CYSTEINE HYDROCHLORIDE

Cysteine Hydrochloride Pharmaceutical Excipient Market Dynamics and Financial Trajectory

Last updated: August 30, 2026

Cysteine hydrochloride is a low-volume, technically important pharmaceutical ingredient used primarily in parenteral nutrition, amino-acid formulations, injectable products, and selected biologic or peptide formulations. Its market is driven less by consumer prescription demand than by sterile manufacturing capacity, neonatal nutrition, hospital supply contracts, and demand for high-purity amino-acid raw materials.

Public companies generally do not report cysteine hydrochloride revenue separately. The commercial outlook is therefore best assessed through downstream product demand, supplier qualification, regulatory requirements, raw-material costs, and manufacturing capacity. The financial trajectory is likely to be steady-to-growing, with stronger pricing and margin potential for GMP-grade, sterile, low-endotoxin material than for food or industrial grades.

What is cysteine hydrochloride used for in pharmaceutical manufacturing?

Cysteine hydrochloride is the hydrochloride salt of cysteine, an amino acid with reducing and formulation-support properties. The material is supplied in anhydrous and monohydrate forms, with the monohydrate form commonly identified by CAS No. 7048-04-6.

Its principal pharmaceutical uses are:

Use	Commercial role	Demand characteristics
Parenteral nutrition	Amino-acid component or additive	Stable hospital and neonatal demand
Injectable formulations	Active ingredient or formulation component	Requires high purity and tight microbiological control
Biologic formulations	Reducing or stabilizing excipient in selected products	Lower volume, higher technical value
Peptide and protein manufacturing	Process reagent or formulation aid	Dependent on contract manufacturing and pipeline activity
Pharmaceutical synthesis	Intermediate or chiral building block	Linked to API production rather than excipient demand
Mucolytic and respiratory products	Related cysteine chemistry, usually not cysteine hydrochloride as an excipient	Product-specific

The regulatory classification depends on the finished product. Cysteine hydrochloride can be an active ingredient in an injectable product, an amino-acid nutrient, a manufacturing reagent, or an excipient. Buyers should not treat all cysteine hydrochloride demand as excipient demand.

How large is the cysteine hydrochloride pharmaceutical market?

No authoritative public source reports a standalone global market size for pharmaceutical-grade cysteine hydrochloride. Market research estimates commonly combine cysteine, L-cysteine, cysteine hydrochloride, food-grade material, cosmetic ingredients, animal nutrition, and pharmaceutical intermediates. Those categories have different prices, specifications, and customer economics.

The addressable pharmaceutical segment is likely small compared with the broader cysteine market. Its value is supported by specification premiums rather than tonnage.

The market has four economic layers:

1. Commodity or technical cysteine.
2. Food and nutraceutical-grade L-cysteine.
3. Pharmaceutical-grade cysteine hydrochloride manufactured under GMP controls.
4. Sterile or injectable-grade material with validated low endotoxin, bioburden, elemental impurity, and particulate controls.

The largest value difference is between pharmaceutical-grade powder and material qualified for injectable manufacturing. The latter requires customer audits, batch traceability, change-control commitments, validated analytical methods, and sustained regulatory support.

What drives demand for pharmaceutical cysteine hydrochloride?

Parenteral nutrition and neonatal care

Parenteral nutrition is the most durable pharmaceutical demand segment. Cysteine hydrochloride may be added to amino-acid solutions used for premature infants and other patients requiring intravenous nutrition. The product label for Cysteine Hydrochloride Injection identifies use as an additive to amino-acid solutions for total parenteral nutrition in pediatric and neonatal patients.[1]

This segment is relatively defensive because demand follows hospital treatment volumes and clinical protocols. It is less exposed to discretionary consumer spending than nutraceutical or cosmetic cysteine.

Biologics and peptide manufacturing

Cysteine residues and thiol chemistry are important in protein conjugation, peptide synthesis, disulfide-bond formation, and selective reduction. Cysteine hydrochloride can be used as a process reagent or formulation component in selected products. Demand in this segment is more volatile because it follows clinical development, commercial launches, and outsourcing activity at contract development and manufacturing organizations.

Amino-acid and injectable product expansion

Growth in sterile injectables, hospital nutrition, and complex generic products supports demand for high-purity amino-acid ingredients. Supply interruptions can create disproportionate commercial impact because customers often qualify only a limited number of sources.

Food and nutraceutical competition

Food-grade L-cysteine and cysteine hydrochloride production can compete for feedstock, fermentation capacity, purification equipment, and manufacturing labor. Pharmaceutical buyers may pay a premium, but they can still face cost pressure when food or nutraceutical demand absorbs available production capacity.

What is the financial trajectory for cysteine hydrochloride suppliers?

The financial trajectory is likely to show moderate volume growth, periodic price volatility, and widening separation between qualified GMP suppliers and commodity producers.

Period	Expected market condition	Financial implication
2020-2022	Supply-chain disruption, freight inflation, inventory building	Higher transaction prices and working-capital requirements
2023-2024	Normalization in logistics with continuing qualification constraints	Price stabilization, but no return to purely commodity economics
2025-2027	Growth in sterile injectables, nutrition, biologics, and peptide manufacturing	Moderate volume growth and stronger demand for qualified suppliers
Longer term	More dual sourcing and regional qualification	Potential margin compression for undifferentiated material

Supplier revenue is generally driven by contract volume multiplied by grade-specific pricing:

Revenue = qualified volume × contracted price × product mix

Margin is more sensitive to product mix than to volume. High-margin contributors include:

• GMP documentation and regulatory support.
• Low-endotoxin or injectable-grade specifications.
• Small-batch and custom packaging.
• Validated analytical testing.
• Stable supply commitments.
• Regulatory change notification and audit support.

Lower-margin contributors include food-grade material, spot-market sales, and large-volume products with multiple approved suppliers.

Public financial statements from major amino-acid and pharmaceutical-ingredient manufacturers generally aggregate these sales into broader pharmaceutical, nutrition, or chemicals divisions. Cysteine hydrochloride is therefore unlikely to be a material disclosed revenue line for a diversified supplier.

Which companies supply pharmaceutical-grade cysteine hydrochloride?

The supply base includes specialized amino-acid manufacturers, pharmaceutical excipient companies, chemical manufacturers, and distributors. Public catalogs identify products from multiple regional suppliers, but catalog availability does not establish regulatory qualification for a specific injectable or biologic application.

The relevant competitive groups are:

Supplier category	Competitive advantage	Main weakness
Large amino-acid manufacturers	Scale, global quality systems, multiple grades	Less flexibility for small customers
Specialized pharmaceutical-ingredient producers	Custom documentation and technical service	Smaller capacity and geographic concentration
Chinese and Indian manufacturers	Cost competitiveness and expanding GMP capacity	Customer-specific qualification and regulatory review
European, Japanese, and U.S. suppliers	Strong documentation and regional trust	Higher production and compliance costs
Distributors and repackagers	Inventory access and local service	Dependence on upstream manufacturers

Purchasers should distinguish between a manufacturer of record and a distributor. The regulatory risk profile changes if the distributor repackages, relabels, or changes the material’s chain of custody.

What regulatory status applies to cysteine hydrochloride?

Cysteine hydrochloride does not have one universal regulatory status. FDA treatment depends on how it is used in the finished product.

The main regulatory pathways are:

• As an active ingredient in a drug product.
• As an amino-acid component in parenteral nutrition.
• As an inactive ingredient or excipient in a finished dosage form.
• As a process aid or manufacturing reagent.
• As a pharmaceutical starting material or intermediate.

The FDA Inactive Ingredient Database is route- and dosage-form-specific. Inclusion of a substance in the database does not create blanket approval for every concentration, route, or product type.[2]

For injectable use, customers typically assess:

• Identity and assay.
• Optical rotation or stereochemical purity.
• Water content.
• Residual solvents.
• Elemental impurities.
• Endotoxin.
• Bioburden.
• Particulate matter.
• Microbial limits.
• Stability and degradation products.
• Container-closure compatibility.
• GMP manufacturing and change-control history.

USP-NF monographs and applicable general chapters can influence specification design and customer qualification, but a pharmacopoeial grade does not eliminate the need for supplier-specific qualification.[3]

What is the Orange Book status of cysteine hydrochloride?

The Orange Book does not provide a standalone patent or exclusivity framework for cysteine hydrochloride as a bulk excipient. FDA Orange Book listings attach to approved finished drug products, not to the commercial existence of a chemical ingredient.[4]

Where cysteine hydrochloride is present in an approved injectable product, the relevant questions are:

• Whether the product has an FDA application number.
• Whether the ingredient is active or inactive in that product.
• Whether FDA lists any patents or exclusivity for the finished product.
• Whether the product is eligible for an abbreviated new drug application.
• Whether the applicant has listed formulation, method-of-use, or manufacturing patents.

For an old amino-acid salt, the compound itself is unlikely to support meaningful composition-of-matter exclusivity. Commercial protection is more likely to arise from formulation design, sterile manufacturing, packaging, process controls, or product-specific regulatory data.

What patents protect cysteine hydrochloride products?

The base compound has limited patent strength because cysteine hydrochloride is an established chemical entity. The most relevant patent categories are:

Formulation patents

Potentially protectable subject matter includes:

• Injectable solutions with defined pH and concentration ranges.
• Stabilized amino-acid compositions.
• Low-oxygen or antioxidant-controlled formulations.
• Compatibility with parenteral nutrition solutions.
• Specific container-closure systems.
• Shelf-life improvements.
• Lyophilized or reconstituted compositions.

Method-of-use patents

Potential claims may cover:

• Pediatric or neonatal nutrition.
• Treatment of specific deficiency states.
• Use in selected injectable regimens.
• Cysteine supplementation in defined patient populations.

Method-of-use claims may have limited commercial value where physicians, hospitals, or nutrition providers use the product outside the claimed method or where competing products can avoid the claim.

Manufacturing and process patents

The most commercially relevant process rights may involve:

• Fermentation or biosynthetic production.
• Purification and crystallization.
• Control of oxidation products.
• Removal of trace metals and endotoxin.
• Stereochemical purity.
• Conversion to the hydrochloride salt.
• Sterile filling and stabilization.

Process patents do not necessarily prevent competitors from selling the same chemical if they use a different manufacturing route.

When does cysteine hydrochloride lose exclusivity?

Cysteine hydrochloride has no single patent expiration date that controls the market. Any original compound patents would generally be expired or commercially irrelevant because the molecule has long pharmaceutical and nutritional use.

Exclusivity instead attaches to individual finished products. Relevant periods may include:

Protection type	Typical commercial effect
New drug application exclusivity	Can delay certain competing FDA applications
Orphan-drug exclusivity	Can restrict approval of the same drug for the same indication
Pediatric exclusivity	Can add six months to qualifying protections
Formulation patent	May delay or complicate generic substitution
Method-of-use patent	Can create labeling or litigation risk
Process patent	May affect manufacturing routes but often has narrower scope

The expiry date must be checked product by product using FDA approval records, Orange Book patent listings, and the relevant patent family.

Which companies are challenging cysteine hydrochloride products?

There is no broadly established, high-profile Paragraph IV dispute associated with cysteine hydrochloride as a chemical ingredient. Paragraph IV challenges apply to patents listed against an approved reference drug, not to a bulk excipient market as a whole.

A generic applicant could challenge a cysteine hydrochloride injectable if:

• The reference product has Orange Book-listed patents.
• The applicant files an ANDA with a Paragraph IV certification.
• The reference product has commercially meaningful sales.
• The formulation or manufacturing process creates a non-infringement or invalidity dispute.

For commodity-grade cysteine hydrochloride, competitive entry usually occurs through supplier qualification rather than patent litigation.

What generic entry risks exist for cysteine hydrochloride products?

Generic risk is high for products with:

• A simple amino-acid solution.
• No active formulation patent.
• Multiple qualified API or excipient sources.
• Limited clinical differentiation.
• Stable FDA-approved manufacturing requirements.

Generic entry risk is lower where the product has:

• Complex sterile manufacturing.
• Proprietary concentration or pH control.
• Container-closure or device integration.
• Difficult stability requirements.
• Limited qualified suppliers.
• Pediatric or neonatal regulatory data.
• Hospital-contract advantages.
• Shortages or supply-chain barriers that discourage new entrants.

The principal barrier is often regulatory and operational rather than patent-based. A new supplier must demonstrate consistent quality, complete documentation, validated testing, and reliable commercial supply.

How strong is the patent estate for cysteine hydrochloride?

The patent estate is weak for the underlying chemical and potentially moderate for specific finished products.

Patent layer	Estimated strength
Cysteine hydrochloride composition	Low
Basic pharmaceutical use	Low
Specific injectable formulation	Low to moderate
Stabilized or extended-shelf-life formulation	Moderate
Sterile manufacturing process	Moderate, depending on claim scope
Packaging and delivery system	Moderate
Product-specific clinical or regulatory exclusivity	Variable

The stronger commercial moat is supplier qualification. A customer may take 12 to 24 months, or longer, to qualify a new source for an injectable application. That period can protect incumbents even where no enforceable patent blocks market entry.

What manufacturing and intellectual-property barriers affect supply?

Cysteine hydrochloride production can use fermentation, chemical synthesis, or hydrolysis-related routes depending on the supplier and product grade. Pharmaceutical buyers focus on consistency and impurity control rather than nominal assay alone.

Key barriers include:

• Control of oxidation to cystine and related impurities.
• Consistent stereochemical purity.
• Moisture and crystallinity control.
• Endotoxin reduction.
• Residual solvent management.
• Batch-to-batch color and appearance.
• Stability under humidity and oxygen exposure.
• Validated cleaning and cross-contamination controls.
• Reliable supply of pharmaceutical-grade starting materials.
• Regulatory support for site changes.

For sterile products, the drug-product manufacturer carries a higher burden than a powder supplier. A change in source, process, manufacturing site, packaging, or specification may require customer notification, comparability data, or regulatory assessment.

How does cysteine hydrochloride compare with other pharmaceutical excipients?

Cysteine hydrochloride has a different commercial profile from large-volume excipients such as sodium chloride, dextrose, mannitol, polysorbates, and polyethylene glycol.

Attribute	Cysteine hydrochloride	Large-volume excipients
Annual volume	Low to moderate	High
Unit value	Higher than commodity salts	Often lower
Technical qualification	High for injectable grade	Variable
Patent dependence	Usually low	Usually low
Supply concentration	Potentially high	Usually broader
Switching cost	High in sterile products	Low to moderate
Price transparency	Limited	Greater for commodities
Shortage sensitivity	High in specialized products	Variable

Cysteine hydrochloride is closer to a specialty amino-acid ingredient than to a generic bulk excipient. Its financial value comes from qualification, documentation, and supply reliability.

What licensing deals affect cysteine hydrochloride?

Public licensing transactions specifically centered on cysteine hydrochloride are uncommon. Licensing is more likely to occur at the level of:

• A finished injectable product.
• A parenteral nutrition portfolio.
• A sterile manufacturing platform.
• A biologic or peptide formulation.
• A fermentation technology.
• A regional distribution agreement.

The absence of publicly disclosed molecule-specific licensing does not mean that commercial agreements do not exist. Supplier contracts are often private and structured around minimum volumes, quality agreements, audit rights, change notification, geographic territories, and price-adjustment mechanisms.

Key Takeaways

• Cysteine hydrochloride is a specialized pharmaceutical amino-acid ingredient with its strongest demand in parenteral nutrition, injectables, biologics, and peptide manufacturing.
• No reliable public source provides a standalone global pharmaceutical cysteine hydrochloride market size or supplier revenue figure.
• The market is driven by grade, qualification, documentation, and supply reliability rather than by compound-level patent exclusivity.
• The underlying chemical has weak patent protection because of its long-established use.
• Formulation, manufacturing, packaging, and method-of-use patents may protect individual finished products.
• Orange Book analysis must be conducted at the finished-drug level.
• Generic entry risk is high for simple injectable formulations and lower where sterile manufacturing, stability, or supplier qualification is difficult.
• The strongest commercial moat is often customer qualification and regulatory history.
• Financial growth should be moderate, with higher margins available for GMP, low-endotoxin, and injectable-grade material.

FAQs

Is cysteine hydrochloride an excipient or an active pharmaceutical ingredient?

It can be either. In parenteral nutrition and cysteine injection products, it may be an active or nutritional ingredient. In selected formulations, it can function as an excipient or processing aid.

Is L-cysteine hydrochloride the same as cysteine hydrochloride?

L-cysteine hydrochloride identifies the biologically relevant stereoisomer. Commercial specifications must confirm stereochemical purity because generic references to cysteine hydrochloride may not define the stereochemical form.

Does cysteine hydrochloride require GMP manufacturing?

Pharmaceutical customers normally require GMP controls for material used in drug manufacturing. Injectable applications impose tighter requirements for microbial control, endotoxin, impurities, traceability, and change management.

Can a pharmaceutical company substitute another cysteine supplier without regulatory review?

Usually not without qualification. A source change may require comparative testing, quality assessment, stability data, customer approval, and, for regulated products, a formal regulatory change assessment.

Is cysteine hydrochloride vulnerable to supply shortages?

Yes. The chemical itself is established, but pharmaceutical-grade and injectable-qualified supply can be concentrated. A shortage at one qualified supplier can affect customers even when food-grade or technical material remains available.

References

1. DailyMed. (n.d.). Cysteine hydrochloride injection, solution. U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/

2. U.S. Food and Drug Administration. (n.d.). Inactive ingredient database. https://www.accessdata.fda.gov/scripts/sda/sdNavigation.cfm?sd=inactiveIngredient/

3. United States Pharmacopeial Convention. (2024). United States Pharmacopeia and National Formulary (USP-NF). https://www.usp.org/

4. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, commonly known as the Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book